GOODWILL AND INTANGIBLE ASSETS

9 Months Ended

Sep. 30, 2012

GOODWILL AND INTANGIBLE ASSETS [Abstract]

NOTE 7—GOODWILL AND INTANGIBLE ASSETS

The gross carrying amounts and net book values of the Company's definite-lived intangible assets are as follows (in thousands):

	Carrying Value, Gross						Accumulated Amortization									Intangible Assets, Net				Weighted
	December 31,				September 30,		December 31,						September 30,			December 31,		September 30,		Average
	2011		Additions		2012		2011			Additions			2012			2011		2012		Useful Life
Customer relationships	$	14,600	$	61,752	$	76,352	$	(9,510	)	$	(2,979	)	$	(12,489	)	$	5,090	$	63,863	12 years
Developed technologies		17,653		58,635		76,288		(13,179	)		(4,521	)		(17,700	)		4,474		58,588	12 years
Trademarks and tradenames		2,300		15,510		17,810		(1,126	)		(3,503	)		(4,629	)		1,174		13,181	5 years
Other contractual agreements		-		3,030		3,030		-			(1,047	)		(1,047	)		-		1,983	2 years
Licenses		79,142		1,928		81,070		(60,355	)		(400	)		(60,755	)		18,787		20,315	Variable
Total definite-lived intangible assets	$	113,695	$	140,855	$	254,550	$	(84,170	)	$	(12,450	)	$	(96,620	)	$	29,525	$	157,930

The expected future annual amortization expense of the Company's intangible assets is as follows (in thousands):

	Amortization
For the Year Ending December 31,	Expense
2012, remainder thereof	$	6,419
2013		23,473
2014		20,750
2015		14,609
2016		13,757
Thereafter		78,922
Total	$	157,930

The Company recognized goodwill of $157.9 million at the Acquisition Date in connection with the Acquisition. Refer to "Note 2. "Acquisition" for further details. Information in regards to changes in the Company's goodwill at September 30, 2012 is as follows (in thousands):

Balance at December 31, 2011	$	-
Additions:
Acquisition of eBioscience		157,929
Effects of foreign currency change		1,491
Balance at September 30, 2012	$	159,420

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References+ Details